Details

Autor(en) / Beteiligte

• Li, Tingting
• Xue, Wenhui
• Zheng, Qingbing
• Song, Shuo
• Yang, Chuanlai
• Xiong, Hualong
• Zhang, Sibo
• Hong, Minqing
• Zhang, Yali
• Yu, Hai
• Zhang, Yuyun
• Sun, Hui
• Huang, Yang
• Deng, Tingting
• Chi, Xin
• Li, Jinjin
• Wang, Shaojuan
• Zhou, Lizhi
• Chen, Tingting
• Wang, Yingbin
• Cheng, Tong
• Zhang, Tianying
• Yuan, Quan
• Zhao, Qinjian
• Zhang, Jun
• McLellan, Jason S
• Zhou, Z Hong
• Zhang, Zheng
• Li, Shaowei
• Gu, Ying
• Xia, Ningshao

Titel

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants

Ist Teil von

• Nature communications, 2021-09, Vol.12 (1), p.5652-5652, Article 5652

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The emergence of numerous variants of SARS-CoV-2, the causative agent of COVID-19, has presented new challenges to the global efforts to control the COVID-19 pandemic. Here, we obtain two cross-neutralizing antibodies (7D6 and 6D6) that target Sarbecoviruses' receptor-binding domain (RBD) with sub-picomolar affinities and potently neutralize authentic SARS-CoV-2. Crystal structures show that both antibodies bind a cryptic site different from that recognized by existing antibodies and highly conserved across Sarbecovirus isolates. Binding of these two antibodies to the RBD clashes with the adjacent N-terminal domain and disrupts the viral spike. Both antibodies confer good resistance to mutations in the currently circulating SARS-CoV-2 variants. Thus, our results have direct relevance to public health as options for passive antibody therapeutics and even active prophylactics. They can also inform the design of pan-sarbecovirus vaccines.